Summit partner Akeso wins China NMPA approval for ivonescimab-chemo in first-line squamous NSCLC
SMMT•China approval expands partnered ivonescimab program
China’s NMPA cleared Akeso’s ivonescimab with chemotherapy for first-line advanced squamous NSCLC, expanding a key partnered program for Summit Therapeutics.
Authorization follows Phase III HARMONi-6, which reported statistically significant overall survival superiority versus tislelizumab with chemotherapy.
Ivonescimab remains unapproved in Summit’s licensed markets; its U.S. BLA for a separate NSCLC setting has a Nov. 14, 2026 PDUFA date.
